Second, our case also highlights the importance of quantitative minimal residual disease (MRD) monitoring: in our patient, increased CBF-MYH11 transcript was the first and only sign raising concern for AML relapse, prompting a rapid reassessment. This evidence concerns the gene MYH11 and acute myeloid leukemia.